AstraZeneca and Bristol-Myers Squibb have announced expansion of their worldwide collaboration to include the development and commercialisation of dapagliflozin in Japan. Dapagliflozin, one of two in
read more » Discuss Add this link to...Bury Add to:
| Bookmarks
AstraZeneca and Bristol-Myers Squibb Company today announced that their marketing authorisation application for ONGLYZA (saxagliptin) received a positive opinion from the Committee for Medicinal Prod
read more » Discuss Add this link to...Bury Add to:
| Bookmarks